-The Hindu Tropical diseases have often been neglected by pharmaceuticals because the size of the drug market is smaller, people have lower incomes and companies are uncertain about IPR January marked an important breakthrough in the fight against tropical diseases. Researchers and the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Delhi found a drug candidate that prevented TB and malaria pathogens from infecting human blood cells. It is not just that...

-Business Standard It is an annual review of the state of IPR protection and enforcement of America's trading partners Notwithstanding the recent bonhomie of sorts between Prime Minister Narendra Modi and US President Barack Obama, India's status as ‘Priority Watch List' country for having an alleged weak intellectual property rights (IPR) and patents regime is unlikely to see any improvement in the US' 2015 Special 301 Report. The 2015 Special 301 Report is...

-The Hindu Business Line Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on...

-The Times of India NEW DELHI: From July 1, you can walk up to a chemist and ask for a 'Jan Aushadhi' brand for your medicine, with the government set to launch its own brand to sell low cost generic medicines. The Centre will procure medicines in bulk from public as well as private drug manufacturing firms and rebrand them under 'Jan Aushadhi'. These will be sold in the retail market at...

-The Hindu Business Line Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month. Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application...